Filing Flows › Absci (ABSI) › Recalls, complaints & regulation
Absci (ABSI): clinical trials
Absci (ABSI) beyond its filings: 1 active clinical trial.
Absci's latest quarter
Absci, Q2 2026: revenue $318K (-46% year over year), net loss $33.2M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Absci have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.